MingZhen Yang

Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, European journal of cancer.

Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer

Q. Cao, Zhengshuai Song, Xiaoping Zhang, 2019, Clinical Cancer Research.

Heterogeneity in the immune microenvironment of bone metastasis in driver‐positive non‐small cell lung cancer

Weihua Luo, Xuchao Zhang, Dongqin Zhu, 2023, Molecular carcinogenesis.

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Jin-Ji Yang, Xuchao Zhang, Hong-Hong Yan, 2022, Journal of Clinical Oncology.

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

Chongrui Xu, Q. Gou, Hong-Hong Yan, 2023, Journal for ImmunoTherapy of Cancer.

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Oncoimmunology.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2023, EClinicalMedicine.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Science bulletin.